Drug Profile
Thrombopoietin - Genentech
Alternative Names: Recombinant human thrombopoietin; rhTPO; TPOLatest Information Update: 05 Dec 2021
Price :
$50
*
At a glance
- Originator Genentech
- Class Antianaemics; Colony-stimulating factors; Glycoproteins; Hepatoprotectants
- Mechanism of Action Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombocytopenia
Most Recent Events
- 22 Oct 2003 Discontinued - Phase-III for Thrombocytopenia in USA (unspecified route)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 31 Jan 2002 This compound is still in active development